Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ:ZVSA)

0.3113 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.3113
Bid (Size) 0.2835 (43)
Ask (Size) 0.2890 (10)
Prev. Close 0.3113
Today's Range 0.3113 - 0.3113
52wk Range 0.3113 - 1.950
Shares Outstanding 8,095,921
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Nasdaq's Delisting Wave: Navigating the Shifting Tides of Public Markets
The Nasdaq Stock Market has seen a notable increase in delistings over recent periods, signaling a recalibration of public market standards and a challenging environment for certain companies. This... 
Via MarketMinute
Topics Bankruptcy Fraud Regulatory Compliance

Performance

YTD
-71.4%
-71.4%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-52.6%
-52.6%
1 Year
-69.9%
-69.9%

More News

Read More
News headline image
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
News headline image
Which stocks are moving after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Top movers analysis one hour before the close of the markets on 2025-07-16: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Top movers in Tuesday's session ↗
Via Chartmill
News headline image
Most active stocks in Tuesday's session ↗
Via Chartmill
News headline image
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday? ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga

Frequently Asked Questions

Is ZyVersa Therapeutics, Inc. - Common Stock publicly traded?
Yes, ZyVersa Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does ZyVersa Therapeutics, Inc. - Common Stock trade on?
ZyVersa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ZyVersa Therapeutics, Inc. - Common Stock?
The ticker symbol for ZyVersa Therapeutics, Inc. - Common Stock is ZVSA on the Nasdaq Stock Market
What is the current price of ZyVersa Therapeutics, Inc. - Common Stock?
The current price of ZyVersa Therapeutics, Inc. - Common Stock is 0.3113
When was ZyVersa Therapeutics, Inc. - Common Stock last traded?
The last trade of ZyVersa Therapeutics, Inc. - Common Stock was at 07/16/25 04:00 PM ET
What is the market capitalization of ZyVersa Therapeutics, Inc. - Common Stock?
The market capitalization of ZyVersa Therapeutics, Inc. - Common Stock is 2.52M
How many shares of ZyVersa Therapeutics, Inc. - Common Stock are outstanding?
ZyVersa Therapeutics, Inc. - Common Stock has 3M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.